Corcept Therapeutics initiated with a Peer Perform at Wolfe Research

Wolfe Research analyst Kalpit Patel initiated coverage of Corcept Therapeutics (CORT) with a Peer Perform rating and no price target The firm’s analysis of Cushing’s syndrome standard of care versus relacorilant and Korlym finds the former may not have the same clinical benefits as the latter, the analyst tells investors.